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Abstract:  
Purpose: To summarize the surface contamination levels of five commonly used 
hazardous drugs in hospital pharmacies, identifying practice patterns associated with 
contamination.  
Methods: Contamination testing data was compiled to evaluate surface contaminants of 
five hazardous drugs (docetaxel, paclitaxel, cyclophosphamide, ifosfamide, and 5-fluorourcil). 
Data from 799 wipe events over 6 years was collected from 338 hospital pharmacies.  The 
contamination level for each drug was categorized as non-detectable (ND; ≤ 10 ng/ft2), low 
(between 10 and ≤ 100ng/ft2), medium (between 100 and ≤ 1,000ng/ft2) or high (> 1,000ng/ft2). 
Surface exposures for each drug were summarized based on location, contamination at first and 
subsequent wipe events, and the use of a closed system transfer device (CSTD).   
Results: The majority of contamination results corresponded to locations at or near 
hazardous drug preparation, but also occurred in areas were hazardous drug was not prepared. 
There was a higher incidence of contamination levels (high, medium, and low, respectively) at 
first wipe event (10.2%, 17.4%, and 17.7%) compared to subsequent wipe events (5.8%, 12.2%, 
and 13.6%) (P<0.0001). There was a lower incidence of contamination levels at institutions that 
used CSTDs (6.3%, 12.8%, and 14.4%) compared to institutions that did not use CSTDs (14.2%, 
17.9%, and 17.3%) (P<0.0001). 
Conclusions: The majority of highest contamination levels corresponded to locations 
where hazardous drugs were prepared. While the incidence of contamination was lower at 
subsequent wipe events and at institutions that used CSTDs, contamination was not completely 
eliminated in either scenario, suggesting that routine contamination testing is beneficial in 
recognizing and correcting practices that lead to surface exposures.  
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Introduction:  
Hazardous drugs are known to be harmful to both healthy and cancerous cells. The 
mechanism of action of hazardous drugs involves interference with cellular synthesis, providing 
therapeutic benefits in cancer patients, but potential harm to healthy human cells.1 The doses at 
which hazardous drugs provide therapeutic benefit have been well studied and are reflected in 
FDA approved dosing of these agents. One element that is often overlooked however is the 
health and safety of the healthcare workers that prepare and administer hazardous drugs, most 
notably pharmacy and nursing personnel.  
The recognition of occupational exposure to hazardous drugs can be traced back to the late 
1970s when biologic monitoring revealed contamination exposure in nurses who handled 
hazardous medications.2 Since then, many studies have documented occupational hazardous drug 
exposures and the resulting adverse effects including mutagenicity and reproductive effects.3-14 
In 2004, the National Institute for Occupational Safety and Health (NIOSH) released an alert 
statement for preventing occupational exposures to antineoplastic and other hazardous drugs in 
healthcare settings. This report specifically detailed that working with or near hazardous drugs in 
a healthcare setting can lead to adverse effects such as skin rashes, infertility, miscarriage, birth 
defects, and possibly leukemia or other cancers.15 After recognizing this contamination and the 
health risks associated with occupational exposure, the healthcare community worked towards 
implementing various measures to minimize exposure to hazardous drugs. In this effort, groups 
including NIOSH, the American Society of Health-System Pharmacists (ASHP), and the 
International Society of Oncology Pharmacy Practitioners (ISOPP) have published guidelines 
addressing the safe handling of hazardous drugs.15-17 Interventions included in these guidelines 
were implementing vertical laminar airflow biological safety cabinets, providing personal 
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protective equipment (PPE) to workers, introducing closed-system transfer devices (CSTDs) to 
hazardous drug preparation and administration, and providing routine medical surveillance 
measures for staff. While each of these methods have reduced occupational exposure to 
hazardous drugs to some extent, surface contamination is still a prevalent concern in hospital 
pharmacies and nursing units,18-23 especially in regards to surface contamination on the outside 
of hazardous drug vials.24-28 
The new USP <800> guidelines add additional information to USP <797> and provides 
workplace standards to protect personnel when handling hazardous drugs. USP <800> 
recommends that environmental wipe sampling for hazardous drug surface residue be performed 
every six months to evaluate for presence of contamination.29 While USP <800> gives 
recommendations for frequency of contamination testing, it does not provide any guidance on 
how extensive the testing should be, including how many locations or how many drugs should be 
tested. Routine monitoring of contamination studies is crucial in allowing institutions to be 
proactive in minimizing hazardous drug contamination. While a site does not want to under-
monitor and risk missing evidence of contamination, it also does not want to over-monitor and 
waste resources. Several studies have reported contamination exposures with and without the use 
of a CSTD30-33; however, no studies to our knowledge have reported additional important 
characteristics of hazardous drug surface contamination including the locations associated with 
higher contamination levels and the incidence of contamination at first wipe event compared to 
subsequent wipe events.  
 The objective of this study is to summarize the surface contamination levels of five 
commonly used hazardous drugs (docetaxel, paclitaxel, cyclophosphamide, ifosfamide, and 5-
fluorourcil) in hospital pharmacies. This study also summarizes the locations that correspond 
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with the highest contamination levels, the incidence of contamination at first wipe event 
compared to subsequent wipe test events, and the incidence of contamination at institutions that 
use CTSDs compared to those that do not use CSTDs.  
 
Methods:  
The hazardous drug surface exposure analysis was performed using ChemoGLOTM (Chapel 
Hill, NC) hazardous drug contamination wipe kits, which analyzes and quantifies the amount of 
surface contaminants of hazardous drugs including docetaxel, methotrexate, cyclophosphamide, 
ifosfamide, 5-FU, paclitaxel, and platinum analogues (e.g. cisplatin, carboplatin, and oxaliplatin). 
Detailed!methods!for!wipe!sampling!and!analyses!of!wipe!samples!have!been!published!
previously.34 
 This study retrospectively evaluated 6 years (from August 2009 to June 2015) of wipe data 
collected in 338 pharmacies from separate healthcare institutions to evaluate patterns and 
characteristics associated with hazardous drug surface exposure. This study focused on the most 
commonly tested drugs: docetaxel, paclitaxel, cyclophosphamide, ifosfamide, and 5-fluorourcil. 
A “wipe event” was defined as each time an institution ordered and performed a wipe study and 
then sent the wipe samples to the lab for analysis.  
For each wipe event, the institution filled out a data collection sheet, indicating the number of 
drugs and locations to be tested. The majority of institutions chose to test for 5 different drugs at 
6 different locations. The data collection sheet also gathered site-specific practices, such as the 
time of day the site performed the wipe testing, whether the area was cleaned prior to testing, and 
the use of CSTDs.  
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Data from 799 different wipe events were included in this study. The highest contamination 
results for each drug among the locations tested were used to summarize the surface 
contamination. Contamination results from the 799 wipe events were categorized into either first 
wipe event or subsequent wipe events. The first wipe event was defined as the first time in which 
an institution ordered and performed a wipe test. Subsequent wipe events were defined as any 
wipe event that occurred at the same institution greater than four weeks after a previous wipe 
event (separate wipe studies are normally performed every one, three or six months). The 
contamination level for each drug at each location was defined as non-detectable (ND); ≤ 10 
ng/ft2 ( ≤ 0.0108 ng/cm2), low; between 10 and ≤ 100 ng/ft2 (between 0.0108 and 0.108 ng/cm2), 
medium; between 100 and ≤ 1,000 ng/ft2 (between 0.108 and 1.08 ng/cm2), or high; > 1,000 
ng/ft2 ( > 1.08 ng/cm2). Factors evaluated included the locations corresponding to highest 
contamination levels for each drug at each site, incidence of contamination levels at first wipe 
event compared to subsequent wipe events, and incidence of contamination at institutions that 
reported use of a CSTD compared to those who did not use a CSTD.  
The Cochran-Armitage Trend Test was performed to evaluate the association between 
overall contamination at subsequent wipe events compared to first wipe event and the association 
between overall contamination at institutions that used CSTDs compared to institutions that did 
not use CSTDs.  
 
Results:  
This study evaluated 799 total wipe events, which consisted of 5,842 individual wipe 
samples. The results included 338 unique healthcare institutions that completed at least one wipe 
event, with 39.64% of these unique institutions completing a subsequent wipe event. The 
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healthcare institutions that completed at least one wipe event represent diverse geographical 
regions within the United States (20.40% Southwestern region; 16.65% Southeastern region; 
13.14% Northeastern region; 29.91% Midwestern region; 18.65% Western region; and 1.25% 
outside of the US). Participating sites reported the time of day the wipe event was performed 
(29.66% reported at the start of the work day; 38.17% reported in the middle of the work day; 
20.28% reported at the end of the work day; and 11.89% did not include information). Sites also 
reported whether the surface tested was cleaned prior to wipe sampling (13.52% reported 
cleaning prior to wipe sampling; 75.09% reported no cleaning prior to wipe sampling; and 
11.39% did not include information). Participating sites were also asked to report whether or not 
CSTDs were used in hazardous drug preparation (75.47% reported using CSTDs; 17.40% 
reported not using CSTDs; and 7.13% did not include information).  
 
Pharmacy locations corresponding with highest contamination levels 
Each institution self-reported on the wipe kit data collection sheet the location in which 
each wipe was performed. All reported locations were categorized into 6 different groupings: 
airfoil, floor below a biologic safety cabinet (BSC), BSC surfaces, pharmacy surfaces (not 
including BSC), floor of the pharmacy (not directly under BSC), and miscellaneous items 
(including phones, keyboards, or chemo transportation bins in the pharmacy). The locations 
corresponding with the highest detected contamination level for each drug per wipe event are 
summarized in Table 1. The majority of the highest contamination results corresponded to 
locations at or near hazardous drug compounding (25.88% airfoil, 22.28% floor below BSC, and 
25.96% at BSC surfaces) with the remaining 25.88% of highest contamination results 
corresponding to areas not located near hazardous drug compounding (12.6% pharmacy surfaces 
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(not including BSC surfaces), 3.9% floors in pharmacy (not under BSC), and 9.4% 
miscellaneous items). 
 
Incidences of contamination for each drug at first and subsequent wipe events 
The contamination results for each drug from each wipe event were analyzed and 
categorized into either first wipe event or subsequent wipe events. The incidence of 
contamination for each drug at first and subsequent wipe events is summarized in Table 2. The 
incidence of wipe results with high, medium, or low contamination was less on subsequent wipe 
events compared to first wipe event, with the exception of the ifosfamide high contamination 
results. There was a lower incidence of high contamination for ifosfamide on first wipe event 
compared to subsequent wipe events (5.84% and 6.61%, respectively). The incidence of wipe 
results with non-detectable contamination was higher for each drug on subsequent wipe events 
compared to first wipe event. The overall incidence of contamination levels (compiling high, 
medium, and low levels) for all drugs was lower at subsequent wipe events compared with first 
wipe event (Z = -8.47; P < 0.0001).  
 
Incidence of contamination for each drug in relation to CSTD use 
Based on institutional practices indicated on the wipe kit data collection sheet, all wipe 
results for each of the 5 drugs tested were stratified into either CSTD users or CSTD non-users. 
For CSTD users, the incidence of various contamination levels for each drug was quantified. The 
same was done for CSTD non-users and the incidence of contamination was compared between 
CSTD users and CSTD non-users.  The results are summarized in Table 3. There was a higher 
incidence of high, medium, or low contamination results in the CSTD non-user’s category 
! 8!
compared to CSTD users, with the exception of 5-FU low contamination results. The 5-FU 
contamination results had equal incidence of low contamination results between CSTD users and 
non-users (12.88%). There was a higher incidence of non-detectable contamination results in the 
CSTD user’s category compared to CSTD non-users. However, as depicted in the results there 
was still low, medium and high levels of exposures of all drugs even with the use of a CSTD 
(14.37%, 12.84%, and 6.30%, respectively). The overall incidence of contamination levels 
(compiling high, medium, and low levels) for all drugs was higher for CSTD non-users 
compared to CSTD users (Z = 8.73; P < 0.0001).  
 
Discussion:  
The data summaries in this study showed that there is a high variability in the surface 
exposures of hazardous drugs in pharmacies. The majority of the highest contamination results 
corresponded to locations where hazardous drugs were prepared. A higher incidence of 
contamination was identified at first wipe event compared to subsequent wipe events (P < 
0.0001). Additionally, a higher incidence of high, medium, and low contamination levels was 
detected at institutions that did not use CSTDs compared to institutions that did use these devices 
(P < 0.0001).  
The contamination results stratified by location are consistent with previous contamination 
results published in the literature showing that surface contamination can be found at the site of 
compounding as well as other locations throughout the pharmacy.18-20 While the majority of 
highest contamination results in this study corresponded to locations involved in the preparation 
of hazardous drugs, it is important to note that the choice of locations tested was at the discretion 
of the institution, and that an institution may have tested locations involved in hazardous drug 
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preparation more frequently. It is also important to note that contamination still exists in other 
areas of the pharmacy not directly involved in compounding (i.e. floors not beneath the BSC, 
pharmacist checking counters, and phones or keyboards). The awareness that contamination 
exposures are occurring at locations at or near the preparation of hazardous drugs suggests that 
additional measures should be taken at these sites to decrease contamination during the 
preparation process, but efforts should not exclude other areas throughout the pharmacy.  
The difference in incidence of contamination between results at first wipe event and 
subsequent wipe events suggests that monitoring is beneficial in recognizing and correcting 
practices that lead to surface exposures. Contamination was not completely eliminated at 
subsequent wipe events, suggesting that continued monitoring is required with the inclusion of 
additional or different strategies to reduce exposure. Hazardous drug contamination wipe studies 
can be performed before and after a change in compounding practice or a change in protective 
measures in a hospital, which allows an institution to quantify the impact the intervention made 
in reducing contamination levels. The ultimate goal is non-detectable levels of contamination in 
each wipe throughout the pharmacy and institution. Thus, hospitals need to continue monitoring 
surface exposures to evaluate if they are maintaining best practices in order to keep 
contamination levels at a minimum.  
The practice of repeated surface contamination testing is consistent with the 
recommendations in USP <800> that testing should be performed routinely (at baseline and then 
at least every 6 months, or more frequently if needed) to confirm containment of the 
contamination.29 While USP <800> does not detail the locations or number of drugs that should 
be tested, the data presented here supports testing a variety of drugs and locations within the 
pharmacy (locations directly and non-directly involved in hazardous drug preparation) for 
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hazardous drugs that are compounded most often at that institution. The majority of institutions 
chose to test six different locations for the five most commonly utilized chemotherapies at their 
institution. Until further research suggests otherwise, the data from this study supports testing a 
minimum of 5 drugs at 6 different locations to get an accurate summary of overall contamination 
levels within a hospital pharmacy.  
One method in decreasing hazardous drug exposure during preparation is the use of a 
CSTD.23, 30-33 The data from this study showed a lower incidence of contamination at institutions 
that used CSTDs in the preparation process. It is important to note that low, medium, and high 
contamination levels still existed at institutions using CSTDs, suggesting that the use of a CSTD 
did not completely remove or prevent all exposures.  The additional use of cleaning products in 
the preparation areas before and after the use of CSTDs addresses both of these issues.34 The 
lower incidence of contamination at institutions that reported use of CSTDs supports the USP 
<800> recommendation to use CSTDs as an adjunctive protection method in preparation and 
administration of hazardous drugs.29 
While the desired goal is to have no surface contamination (non-detectable), it should be 
evident that this is not achieved in all situations and there is a high variability in surface 
exposures of hazardous drugs in pharmacies. Even at institutions where best practices are 
implemented, the data in this study shows that surface contamination was detectable in variable 
and unpredictable levels.  The reasons for this are unclear but may include spills or breaking of a 
vial, not implementing all best practices, inconsistent use of safety practices and PPE, variability 
in the appropriate use of CSTDs, the ability of the CSTD to be truly closed, and external 
contamination of hazardous drug vials from the manufacturer.24-28,35 So while non-detectable 
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contamination is not always possible, routine contamination testing is useful in identifying areas 
of contamination and implementing changes to prevent future contamination.  
A limitation of this study was the exclusion of contamination results from nursing and drug 
administration areas. The 2004 NIOSH Alert detailed that occupational exposure to hazardous 
drugs can occur at many points in the medication use process from procurement of the drugs to 
administration of drugs to patients.15 However, the focus of this study was on pharmacy practice 
patterns and the incidence of exposures of hazardous drugs.  Future research and studies in other 
areas, such as nursing and administration areas, are needed. In regards to pharmacy-specific 
practices, additional characteristics that should be evalulated in future studies include the volume 
of chemotherapy prepartaions at each institution daily, which CSTD was used, whether CSTDs 
were used in all preparations including 5-Fluorouracil pumps, the level of experience of staff 
compounding the hazardous drugs, and the cleaning processes within the pharmacies.  
 
Conclusions:  
To date this is the largest study evaluating pharmacy practices and characteristics associated 
with levels of hazardous drug surface contamination.  The highest contamination results occurred 
at locations both directly and indirectly involved in hazardous drug compounding, suggesting 
drug exposures can travel throughout the pharmacy. A higher incidence of contamination was 
identified at first wipe event compared to subsequent wipe events, suggesting that monitoring is 
beneficial in recognizing and correcting practices that lead to hazardous drug surface exposures. 
Contaminations were not completely eliminated at subsequent wipe events, suggesting that 
continued monitoring is required with the inclusion of additional or different strategies to reduce 
exposures. A higher incidence of high, medium, and low contamination levels was detected at 
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institutions that did not use a CSTD compared to institutions that did use these devices. 
However, the use of a CSTD did not completely prevent all exposures, further suggesting that 
multiple practices, such as combining a CSTD with a cleaning product, should be implemented 
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Table 1: Occurance of pharmacy locations with highest drug contamination levels 
Drug Number of Contaminations 
(% Contamination by Pharmacy Location) 






































































Ifosfamide 65 45 52 19 2 13 
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Table 2: Incidence of contamination for each drug at first and subsequent wipe events 

























1st wipe (n = 336) 
Subsequent (n = 460) 
4.76% 
 
1.96% 18.45% 8.70% 21.13% 16.96% 55.65% 72.39% 
Docetaxel 
1st wipe (n = 336) 
Subsequent (n = 460) 
3.27% 
 
1.30% 14.58% 5.65% 17.26% 10.22% 64.88% 82.83% 
Cyclophosphamide 
1st wipe (n = 293) 
Subsequent (n = 454) 
16.04% 
 
7.05% 22.87% 20.26% 21.16% 16.08% 39.93% 56.61% 
Ifosfamide  
1st wipe (n = 291) 
5.84% 
 
6.61% 13.06% 9.69% 13.75% 12.78% 67.35% 70.93% 
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Subsequent (n = 454) 
5-FU 
1st wipe (n = 287) 
Subsequent (n = 451) 
23.00% 
 
12.42% 18.12% 17.07% 14.63% 11.75% 44.25% 58.76% 





ALow Contamination: between 10 and ≤ 100 ng/ft2 (between 0.0108 and 0.108 ng/cm2) 
BMedium Contamination: between 100 and ≤ 1,000 ng/ft2 (between 0.108 and 1.08 ng/cm2) 
CHigh Contamination: > 1,000 ng/ft2 ( > 1.08 ng/cm2) 
DNon-detectable Contamination (ND): ≤ 10 ng/ft2 ( ≤ 0.0108 ng/cm2) 
*P-value comparing the overall results for high medium, low and non-detectable contamination levels at 1st and subsequent results 






Table 3: Incidence of contamination for each drug with and without the use of a CSTD 








CSTD No CSTD CSTD No CSTD CSTD No CSTD CSTD No CSTD 
Paclitaxel 
CSTD (n = 605) 
No CSTD (n = 137) 
2.31% 5.84% 10.58% 17.52% 15.87% 24.82% 71.24% 51.82% 
Docetaxel 
CSTD (n = 605) 
No CSTD (n = 137) 
1.82% 4.38% 6.28% 13.87% 12.23% 14.60% 79.67% 67.15% 
Cyclophosphamide 
CSTD (n = 605) 
No CSTD (n = 137) 
7.44% 24.09% 20.66% 24.82% 17.69% 19.71% 54.21% 31.39% 
Ifosfamide  
CSTD (n = 601) 
No CSTD (n = 135) 
5.32% 10.37% 9.15% 17.04% 13.14% 14.07% 72.38% 58.52% 
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5-FU 
CSTD (n = 598) 
No CSTD (n = 132) 
14.72% 26.52% 17.56% 15.91% 12.88% 12.88% 54.85% 44.70% 






12.84% 17.85% 14.37% 17.26% 66.49% 50.74% 
ALow Contamination: between 10 and ≤ 100 ng/ft2 (between 0.0108 and 0.108 ng/cm2) 
BMedium Contamination: between 100 and ≤ 1,000 ng/ft2 (between 0.108 and 1.08 ng/cm2) 
CHigh Contamination: > 1,000 ng/ft2 ( > 1.08 ng/cm2) 
DNon-detectable Contamination (ND): ≤ 10 ng/ft2 ( ≤ 0.0108 ng/cm2) 
*P-value comparing the overall results for high, medium, low and non-detectable contamination levels with and without the use of a 
CTSD is P < 0.0001 for all groups. 
 
 
